Skip to main content
. 2020 Apr 20;2020(4):CD012395. doi: 10.1002/14651858.CD012395.pub2

3.2. Analysis.

Comparison 3 Patisiran versus placebo in TTR‐FAP, Outcome 2 Severity of peripheral neuropathy (expressed as the change from baseline in the mNIS+7Alnylam), at 18 months.